title: Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation.
abstract: On the basis of transplantation data from the Japan Society for Hematopoietic Cell Transplantation, we retrospectively analyzed the impact of cytogenetics at diagnosis on the outcome of transplantation in 628 patients with acute myeloid leukemia who underwent autologous (n = 200), allogeneic related (n = 363), or allogenic unrelated (n = 65) stem cell transplantation (SCT) at first complete remission. For autologous SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .017) and a significantly higher event-free survival (EFS) (P = .013) compared with those at intermediate risk. For allogeneic SCT, patients at good cytogenetic risk had a significantly lower relapse rate (P = .019) and insignificantly higher EFS (P = .093) than those at poor risk. For unrelated SCT, there was no significant difference in relapse rate or EFS between patients at good risk and those at intermediate risk. Comparison of the 3 transplantation modalities revealed that autologous SCT patients had a significantly higher incidence of relapse compared with related or unrelated SCT patients in the intermediate-risk group but not in the good-risk group. However, there were no significant differences in EFS among the 3 transplant modalities in either of these 2 risk groups. In multivariate analysis, cytogenetics was found to be an independent predictor of relapse as well as of treatment failure.
authors.affiliation: Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan. ogawah@imed3.med.osaka-u.ac.jp
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ogawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ikegame
authors.forename: Manabu
authors.initials: M
authors.lastname: Kawakami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Takahiro
authors.initials: T
authors.lastname: Karasuno
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sao
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kodera
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Okamoto
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Koji
authors.initials: K
authors.lastname: Iwato
authors.forename: Atsuo
authors.initials: A
authors.lastname: Maruta
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.forename: Keisei
authors.initials: K
authors.lastname: Kawa
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002869:Chromosome Aberrations; D003582:Cytogenetics; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007564:Japan; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D012008:Recurrence; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome